
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
An update : Congenital CMV Puzzler : Facial droop and confusion overtake teen Dermcase : Adolescent distressed by scaly papules and plaques Menses : A vital sign of bone health






